We use cookies to ensure that we give you the best experience on our website Learn more

Feb 18, 2019

12th International Conference on Advanced Technologies & Treatments for Diabetes

REDUCTION OF GLYCEMIC VARIABILITY (GV) BY HAEMODIALYSIS IN TYPE 2 DIABETES

;

cgms

type 2 diabetes

haemodialysis

Abstract

Abstract

thumbnail

Keywords

cgms

type 2 diabetes

haemodialysis

Abstract

REDUCTION OF GLYCEMIC VARIABILITY BY HAEMODIALYSIS IN TYPE 2 DIABETES Background: The HbA1c is a set of parameters of glycemic control in patients with type 2 diabetes (T2D), however this markers do not reflect well glycemic control in T2D patients on haemodialysis (HD). The glycemic variability (VG) could be assessed by continuous glucose monitoring (CGM). The CGM can evaluate the GV by coefficient of variation (CoV) and Mean amplitude of glucose excursion (MAGE). We aimed to evaluate the VG by CGM in T2D patients on chronic HD. Methods: We used a 6-day CGM to monitor glucose levels in 10 HD-T2D patients including 2 days before (PRE-HD), 1 day during (INTRA-HD) and 3 days without dialysis session (POST-HD). Results: T2D duration was 13.9±2.4 (years) and HD duration was 3.7±0.3(years). The mean of HbA1c was 6,41±0,2 %, the CoV mean 29.6±1.7 % and the mean of MAGE was 267.5±16.7. We found a reduction of CoV and MAGE between PRE-HD 23.6±2.6% vs INTRA-HD 13.4±1.5%, P < 0.01; PRE-HD 142.4±19.5 vs INTRA-HD 77.1±12.3, P < 0.01; an increase of CoV and MAGE between INTRA-HD 13.4±1.5% vs POST-HD 24.4±2.8% P < 0.05; 77.1±12.3 vs 145.5±20.1, P < 0.05. The mean of CoV-PRE-HD and MAGE-PRE-HD were correlated positively (r = 0.87, P < 0.01); the mean of CoV-INTRA-HD and MAGE-INTRA-HD were correlated positively (r = 0.67, P < 0.01). No significant association with HbA1c was found. Conclusion: The HD reduces the CoV by CGM with no associations with HbA1c. The CGM could be a validated marker of glycemic control in HD-T2D patients.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.